Are you attending the @MDAorg Clinical & Scientific Conference? Check out the two #OPMD sessions highlighting data and updates from our clinical program and presented by Benitec CEO Jerel Banks, M.D., Ph.D. We hope to see you there! #MDAConference #MuscularDystrophy

We’re honored to participate in this year’s @MDAorg Gene Therapy Summit & engage with leading physicians & researchers in #musculardystrophy as we continue to drive important progress in innovations for #neuromuscular diseases. More: benitec.com

We are dedicated to the advancement of our unique AAV-based gene therapy, BB-301, to transform the treatment landscape for Oculopharyngeal Muscular Dystrophy (OPMD). Learn more: benitec.com #meded

Removal from Official List $BLT - bit.ly/3bcoXl7

Implementation of Scheme of Arrangement $BLT - bit.ly/3b6iet0

Benitec Inc Appoints Edward Smith to the Board of Directors $BLT - bit.ly/3abMTDS

Voluntary delisting of ADSs and Warrants from Nasdaq $BLT - bit.ly/3dN2Vr7

Position on FIRB approval $BLT - bit.ly/2UtqH3t

Suspension from Official Quotation $BLT - bit.ly/3bwsV7S

Trading Halt $BLT - bit.ly/39rM1L2

Pause in Trading $BLT - bit.ly/2xxvCYo

Court approves re-domiciliation scheme $BLT - bit.ly/2UNQmTo

Change of Director's Interest Notice $BLT - bit.ly/3bDQUCu

Results of Scheme Meeting $BLT - bit.ly/33K1eWy

Chairperson's address and presentation for Scheme Meeting $BLT - bit.ly/2UAKsoT

COVID-19 information relating to Scheme Meeting $BLT - bit.ly/2QpYb0f

Appendix 4D and Half Year Report $BLT - bit.ly/37UX8vi

Scheme Booklet $BLT - bit.ly/2whKcTd

Court orders convening of Scheme Meeting $BLT - bit.ly/31wh5XP

Appendix 4C - quarterly $BLT - bit.ly/2GBC2XN